OFS Capital Corporation Announces Date for Its Third Quarter 2026 Earnings Release and Conference Call

Wed, 21 Oct 2026 08:00:00 -0400

CHICAGO--(BUSINESS WIRE)-- OFS Capital Corporation (Nasdaq: OFS) (“OFS Capital”), a business development company, announced today that it will report its third quarter 2026 earnings results after the close of the stock market on Thursday, October 29, 2026.

A conference call is scheduled for Friday, October 30, 2026 at 10:00 a.m. Eastern Time to discuss OFS Capital’s financial results and business. Bilal Rashid, Chairman & Chief Executive Officer, will host the call, along with Kyle Spina, Chief Financial Officer & Treasurer.

Interested parties can listen to the call via the following:

OFS Capital Corporation Announces Date for Its Third Quarter 2026 Earnings Release and Conference Call

Wed, 21 Oct 2026 08:00:00 -0400

Interested parties can listen to the call via the following:

Form 8-K OFS Capital Corp For: Oct 05

Tue, 06 Oct 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20261006/27152127.html

OFS Capital Corporation Announces Partial Monetization of Equity Interest for $52.3 Million of Gross Proceeds

Tue, 06 Oct 2026 08:00:00 -0400

CHICAGO--(BUSINESS WIRE)-- OFS Capital Corporation (Nasdaq: OFS) (“OFS Capital”; the “Company”), a business development company, announced today the closing of a transaction through OFS SBIC I, LP (“SBIC I LP”), a wholly owned subsidiary of OFS Capital. On October 5, 2026, SBIC I LP admitted a third-party investor (the “New Investor”) as a limited partner, which acquired approximately 57% of the limited partnership interests of SBIC I LP in such transaction (the “Transaction”).

SBIC I LP holds 400 Class A shares of Pfanstiehl Holdings, Inc., a global manufacturer of high-purity pharmaceutical ingredients, which represented approximately 84.0% of the

OFS Capital Corporation Announces Partial Monetization of Equity Interest for $52.3 Million of Gross Proceeds

Tue, 06 Oct 2026 08:00:00 -0400

SBIC I LP holds 400 Class A shares of Pfanstiehl Holdings, Inc., a global manufacturer of high-purity pharmaceutical ingredients, which represented approximately 84.0% of the

Form N-23C-2 OFS Capital Corp For: Aug 28

Fri, 28 Aug 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260828/26993636.html

Form N-23C-2 OFS Capital Corp For: Aug 28

Fri, 28 Aug 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260828/26993636.html

Form 8-K OFS Capital Corp For: Aug 28

Fri, 28 Aug 2026 09:11:00 -0400

si-local-file:///var/storage/secattach/20260828/26993606.html

Form 8-K OFS Capital Corp For: Aug 28

Fri, 28 Aug 2026 09:11:00 -0400

si-local-file:///var/storage/secattach/20260828/26993606.html

Form 8-K OFS Capital Corp For: Aug 11

Tue, 11 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260811/26906464.html

Form 8-K OFS Capital Corp For: Aug 11

Tue, 11 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260811/26906464.html

Form 10-Q OFS Capital Corp For: Jun 30

Fri, 31 Jul 2026 06:00:00 -0400

http://archive.fast-edgar.com/20260731/AFZZQ22CZ22PO2Z2222K22ZZAVN9ZZN86H82

Filed on: July 31, 2026

Form 10-Q OFS Capital Corp For: Jun 30

Fri, 31 Jul 2026 06:00:00 -0400

http://archive.fast-edgar.com/20260731/AFZZQ22CZ22PO2Z2222K22ZZAVN9ZZN86H82

Filed on: July 31, 2026

OFS Capital (OFS) Tops Q2 EPS by 19c

Thu, 30 Jul 2026 16:38:53 -0400

OFS Capital (NASDAQ: OFS) reported Q2 EPS of $0.42, $0.19 better than the analyst estimate of $0.23. Revenue for the quarter came in at $6.84 million versus the consensus estimate of $9.68 million.

For earnings history and earnings-related data on OFS Capital (OFS) click here.

OFS Capital Corporation Announces Second Quarter 2026 Financial Results